Literature DB >> 20372852

Cigarette smoking, TP53 Arg72Pro, TP53BP1 Asp353Glu and the risk of lung cancer in a Japanese population.

Chikako Kiyohara1, Takahiko Horiuchi, Yoshihiro Miyake, Koichi Takayama, Yoichi Nakanishi.   

Abstract

The tumor suppressor protein p53 (TP53) plays a central role in directing cellular responses to DNA damage. Tumor protein 53-binding protein 1 (TP53BP1) binds to TP53 and has a potential role in DNA damage responses. DNA damage-dependent interaction between TP53 and TP53BP1 may contribute to lung cancer risk. We aimed to assess whether or not TP53 and TP53BP1 genetic polymorphisms modulate lung cancer susceptibility in a Japanese population. We investigated the relationship of the TP53 Arg72Pro and TP53BP1 Asp353Glu polymorphisms to lung cancer risk with special reference to polymorphism-polymorphism and polymorphism-smoking interactions among 462 lung cancer cases and 379 controls. The Glu/Glu genotype of TP53BP1 Asp353Glu polymorphism was associated with a decreased risk of lung cancer [odds ratio (OR) = 0.46, 95% confidence interval (CI) = 0.29-0.74]. There was no polymorphism-smoking interaction. A combination of the Pro allele carriage of the TP53 Arg72Pro polymorphism and the Glu/Glu genotype of the TP53BP1 Asp353Glu polymorphism was associated with a decreased risk of lung cancer (OR=0.38, 95% CI=0.17-0.83). The multiplicative interaction measure was statistically significant (OR for interaction = 2.93, 95% CI=1.24-6.93). The relative excess risk due to interaction and attributable proportion due to interaction were 0.74 (95% CI=0.38-1.20) and 0.63 (95% CI=0.05-1.21), respectively. Both the additive interaction measures were not equal to zero, suggesting that the existence of a biological interaction. Our findings indicate the possible association of the Glu allele of the TP53BP1 Asp353Glu polymorphism with lower risk of lung cancer especially among the Pro allele carriers of the TP53 Arg72Pro polymorphism.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20372852     DOI: 10.3892/or_00000772

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  9 in total

1.  Association between the TP53 polymorphisms and lung cancer risk: a meta-analysis.

Authors:  Xiang-Hua Ye; Zhi-Bin Bu; Jie Feng; Ling Peng; Xin-Biao Liao; Xin-Li Zhu; Xiao-Li Sun; Hao-Gang Yu; Dan-Fang Yan; Sen-Xiang Yan
Journal:  Mol Biol Rep       Date:  2013-11-23       Impact factor: 2.316

2.  Variant TP53BP1 rs560191 G>C is associated with risk of gastric cardia adenocarcinoma in a Chinese Han population.

Authors:  Sheng Zhang; Weifeng Tang; Guowen Ding; Chao Liu; Ruiping Liu; Suocheng Chen; Haiyong Gu; Chunzhao Yu
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

Review 3.  The association between TP53 Arg72Pro polymorphism and lung cancer susceptibility: evidence from 30,038 subjects.

Authors:  Qian Qiao; Weiguo Hu
Journal:  Lung       Date:  2013-04-18       Impact factor: 2.584

4.  Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.

Authors:  I-Chen Wu; Yang Zhao; Rihong Zhai; Chen-yu Liu; Feng Chen; Monica Ter-Minassian; Kofi Asomaning; Li Su; Rebecca S Heist; Matthew H Kulke; Geoffrey Liu; David C Christiani
Journal:  Carcinogenesis       Date:  2011-01-06       Impact factor: 4.944

5.  Lung cancer risk in relation to TP53 codon 47 and codon 72 polymorphism in Bangladeshi population.

Authors:  Md Shaki Mostaid; Maizbha Uddin Ahmed; Mohammad Safiqul Islam; Muhammad Shahdaat Bin Sayeed; Abul Hasnat
Journal:  Tumour Biol       Date:  2014-07-18

6.  Influence of common genetic variation on lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls.

Authors:  Maria N Timofeeva; Rayjean J Hung; Thorunn Rafnar; David C Christiani; John K Field; Heike Bickeböller; Angela Risch; James D McKay; Yufei Wang; Juncheng Dai; Valerie Gaborieau; John McLaughlin; Darren Brenner; Steven A Narod; Neil E Caporaso; Demetrius Albanes; Michael Thun; Timothy Eisen; H-Erich Wichmann; Albert Rosenberger; Younghun Han; Wei Chen; Dakai Zhu; Margaret Spitz; Xifeng Wu; Mala Pande; Yang Zhao; David Zaridze; Neonilia Szeszenia-Dabrowska; Jolanta Lissowska; Peter Rudnai; Eleonora Fabianova; Dana Mates; Vladimir Bencko; Lenka Foretova; Vladimir Janout; Hans E Krokan; Maiken Elvestad Gabrielsen; Frank Skorpen; Lars Vatten; Inger Njølstad; Chu Chen; Gary Goodman; Mark Lathrop; Simone Benhamou; Tõnu Vooder; Kristjan Välk; Mari Nelis; Andres Metspalu; Olaide Raji; Ying Chen; John Gosney; Triantafillos Liloglou; Thomas Muley; Hendrik Dienemann; Gudmar Thorleifsson; Hongbing Shen; Kari Stefansson; Paul Brennan; Christopher I Amos; Richard Houlston; Maria Teresa Landi
Journal:  Hum Mol Genet       Date:  2012-08-16       Impact factor: 6.150

7.  Impact of TP53 codon 72 and MDM2 SNP 309 polymorphisms in pancreatic ductal adenocarcinoma.

Authors:  Yasuki Hori; Katsuyuki Miyabe; Michihiro Yoshida; Takahiro Nakazawa; Kazuki Hayashi; Itaru Naitoh; Shuya Shimizu; Hiromu Kondo; Yuji Nishi; Shuichiro Umemura; Akihisa Kato; Hirotaka Ohara; Hiroshi Inagaki; Takashi Joh
Journal:  PLoS One       Date:  2015-03-03       Impact factor: 3.240

Review 8.  Lack of association of the TP53BP1 Glu353Asp polymorphism with risk of cancer: a systematic review and meta-analysis.

Authors:  Lei Liu; Jinghua Jiao; Yu Wang; Dong Zhang; Jingyang Wu; Desheng Huang
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

9.  The Association of Aging-Related Polymorphisms with Susceptibility to Lung Cancer: A Case-Control Study in a Japanese Population.

Authors:  Hironobu Furuie; Masako Arimura-Omori; Naoki Hamada; Toyoshi Yanagihara; Chikako Kiyohara
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.